BDSI - BioDelivery Sciences International, Inc.
| Previous Close | 5.27 |
| Open | 5.30 |
| Bid | 5.16 x 800 |
| Ask | 5.17 x 1400 |
| Day's Range | 5.04 - 5.33 |
| 52 Week Range | 1.70 - 5.36 |
| Volume | 472,136 |
| Avg. Volume | 839,991 |
| Market Cap | 367.536M |
| Beta (3Y Monthly) | -0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings Date | May 8, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.25 |
- Zacks•2 days ago
Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.
- Zacks•3 days ago
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of BDSI earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 BioDelivery Sciences International Inc Earnings Call
- Zacks•6 days ago
BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.
Motley Fool•7 days agoBiodelivery Sciences International Inc (BDSI) Q4 2018 Earnings Conference Call Transcript
BDSI earnings call for the period ending December 31, 2018.
- Associated Press•7 days ago
BioDelivery: 4Q Earnings Snapshot
On a per-share basis, the Raleigh, North Carolina-based company said it had a loss of 10 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- ACCESSWIRE•7 days ago
BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations
BELBUCA® prescription growth further accelerated to an all-time high during the fourth quarter Company increases Belbuca 2019 net sales expectations to $80-$85 million Operating cash flow to become positive ...
- ACCESSWIRE•7 days ago
BioDelivery Sciences International, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March ...
- Zacks•8 days ago
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
- GlobeNewswire•9 days ago
BioDelivery Sciences Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
BOSTON, March 12, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether BioDelivery.
- Zacks•9 days ago
Alnylam Files Application for Hypertension Candidate in UK
Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.
- Simply Wall St.•10 days ago
What Kind Of Shareholder Appears On The BioDelivery Sciences International, Inc.’s (NASDAQ:BDSI) Shareholder Register?
Every investor in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companiesRead More...
- Zacks•10 days ago
AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.
- Zacks•10 days ago
What Makes BioDelivery Sciences International (BDSI) a Strong Momentum Stock: Buy Now?
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks•10 days ago
Will the Decade-Old Bull Market Momentum Last? 5 Picks
After a disappointing 2018, in which all the three major stock indexes closed in the red owing to severe volatility, Wall Street has made a spectacular comeback this year.
- Zacks•16 days ago
What's in Store for BioSpecifics (BSTC) This Earnings Season?
BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.
- Zacks•16 days ago
What's in the Cards for Corbus (CRBP) This Earnings Season?
Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.
- Zacks•16 days ago
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Zacks•16 days ago
Champions Oncology (CSBR) Q3 Earnings: What's in Store?
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
- Zacks•20 days ago
Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up
Endo's (ENDP) earnings and revenues top expectations in the fourth quarter.
- Zacks•20 days ago
Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018
Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.
- Zacks•20 days ago
The Meet Group (MEET) to Report Q4 Earnings: What's in Store?
The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.
- Zacks•21 days ago
Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat
Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.
- Zacks•21 days ago
Zacks.com featured expert Kevin Matras highlights: First, Clearfield, BioDelivery Sciences International, MGIC Investment and Kratos Defense & Security Solutions
Zacks.com featured expert Kevin Matras highlights: First, Clearfield, BioDelivery Sciences International, MGIC Investment and Kratos Defense & Security Solutions
- Zacks•22 days ago
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
Focus of Editas' (EDIT) fourth-quarter conference call is likely to be on its pipeline.
